Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
This clinical practice guideline was produced jointly by the American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) (OH CCO). The aim of this work is to provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) without driver alterations. A guideline update for patients with stage IV NSCLC with driver alterations will be published separately. The joint guideline is published in the Journal of Clinical Oncology (JCO) and can be accessed directly from the link "Full Report” below.
Patients with stage IV NSCLC without driver alterations in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) (with known EGFR and ALK) status (plus programmed death ligand 1 (PD-L1) tumor proportion score (TPS) test results available to the clinician being optimal).*
Intended Guideline Users:
Oncology care providers (including primary care physicians, specialists, nurses, social workers, and any other relevant member of a comprehensive multidisciplinary cancer care team), patients, and their caregivers in North America and beyond.
What systemic therapy treatment options should be offered to patients with stage IV non–small-cell lung cancer (NSCLC) without driver alterations, depending on the subtype of the patient’s cancer?